Best of ASCO - 2014 Annual Meeting

 

Welcome

Esophageal or Gastric Cancer

Gastrointestinal (Noncolorectal) Cancer

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
KRAS amplification and mutation as independent events in gastroesophageal adenocarcinomas (GEA).

Joseph Chao

e15565

A digital pathology demonstration of an "immune hot" ICOS+/CD45RO+ immunephenotype and the impact on survival in patients with esophageal adenocarcinoma.

Matthew Philip Humphries

4062

A landscape of circulating tumor DNA in esophageal adenocarcinoma and squamous cell carcinoma.

Kabir Mody

4070

A multicenter, single-armed, prospective phase II study of apatinib combined with chemotherapy neoadjuvant for locally advanced gastric cancer.

JianXian Lin

e15508

A novel EUS-guided liquid fiducial marker for image-guided radiotherapy in esophageal cancer: The safety and efficacy in vitro and vivo evaluations.

Liangchao Sun

e15573

A phase Ib study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.

Yee Chao

4030

A phase Ib study of oraxol in combination with ramucirumab in patients with gastric or esophageal cancers who failed previous chemotherapy.

Yi-Ping Hung

e15518

A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: The PERFECT trial.

Tom van den Ende

4045

A phase II study of S-1, oxaliplatin, and nab-paclitaxel, and itraconazole aimed at conversion surgery for advanced and recurrent gastric cancer.

Yoshihiko Nakamoto

4026

A phase II study of TAS-102 in combination with ramucirumab in advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Rutika Mehta

TPS4149

A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC).

Min Hee Hong

4027

A pilot study of neoadjuvant FOLFIRINOX followed by chemoradiation for gastric and gastroesophageal cancer: Preliminary results.

Jennifer Yon-Li Wo

4057

A single-arm, open phase II clinical trial of anti-programmed death-1 antibody SHR-1210 combined with nimotuzumab as second-line treatment of advanced esophageal squamous cell carcinoma.

Feng Wang

TPS4147

Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: A multicenter, randomized phase II study (PRODIGE 19).

Clarisse Eveno

4019

Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC).

Maria Alsina

4043

Apatinib affects the proliferation, migration and apoptosis of esophageal cancer cells both in vitro and in xenografts by regulating Ras/Raf/MEK/ERK and JAK2/STAT3 signaling pathways.

Jingping Yu

e15501

Apatinib in the treatment of non-operable or advanced gastric cancer: Evidence of efficacy and safety in a real-world study.

Ligang Xing

e15515

Apatinib inhibits tumor progression and promotes antitumor efficacy of cytotoxic drugs in esophageal squamous cell carcinoma.

Yanyan Chi

e15554

ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).

Se Hoon Park

4001

Assessment of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial.

Federica Morano

TPS4151

Association between heart dosimetric parameters, cardiac events and overall survival for patients with stage III esophageal cancer treated with definitive radiotherapy.

Guoxin Cai

e15561

Association between molecular subtype of esophageal squamous cell carcinoma and survival of patients.

Denis S. Kutilin

e15520

Association of CDH1 mutation with prognosis in gastric adenocarcinoma.

Xiangyang Yu

e15514

Association of frequent amplification of chromosome 11q13 in esophageal squamous cell cancer with clinical benefit to immune check point blockade.

Feng Wang

4036

Association of high copy number instability (CNI) score with prognosis in patients with gastric cancer after surgical resection.

Yanling Zhang

e15552

Best supportive care (BSC) with or without low-dose chemotherapy (chemo) in frail elderly patients with advanced gastroesophageal cancer (aGOAC): The uncertain randomization of the GO2 phase III trial.

Daniel Swinson

4051

CA224-060: A randomized, open label, phase II trial of relatlimab (anti-LAG-3) and nivolumab with chemotherapy versus nivolumab with chemotherapy as first-line treatment in patients with gastric or gastroesophageal junction adenocarcinoma.

Kynan Feeney

TPS4143

Camrelizumab combined with capecitabine and oxaliplatin followed by camrelizumab and apatinib as first-line therapy for advanced or metastatic gastric or gastroesophageal junction cancer: Updated results from a multicenter, open label phase II trial.

Lin Shen

4031

Can hormone receptors prevent metastatic spread of gastric cancer?

Irina V. Kaplieva

e15527

Clinical and molecular factors predicting resistance to first-line (1L) FOLFOX in patients (pts) with advanced esophagogastric cancer (EGA) and patterns of subsequent therapy.

Megan Greally

4047

Clinical efficacy and safety in gastric cancer patients treated with apatinib: A retrospective real-world study.

Ning Li

e15522

Clinical implication of telomere length-related polymorphisms in gastric cardia adenocarcinoma.

Nasha Zhang

e15502

Clinical significance of peritoneal molecular markers in patients with locally advanced gastric cancer (LAGC) without macroscopic peritoneal implants treated with perioperative chemotherapy (ChT).

Luis Paul Del Carpio Huerta

e15583

Clinicopathological and prognostic significance of microsatellit instability (MSI) status and PDl-1 expression in Turkish patients with gastric cancer.

Ibrahim Yildiz

e15538

Clinicopathological features of Epstein–Barr virus associated gastric carcinoma with submucosal invasion.

Hiroki Osumi

4029

Combining neoadjuvant chemoradiation with adjuvant chemotherapy in multimodality treatment for patients with potentially curable esophageal carcinoma.

Ruta Arays

e15574

Comparison of D2 and D2 plus radical surgery for advanced distal gastric cancer: A randomized controlled study.

Pengfei Yu

e15546

Comparison of efficacy and safety of second-line palliative chemotherapy with paclitaxel plus raltitrexed and paclitaxel alone in patients with metastatic gastric adenocarcinoma: A randomized phase II trial.

Xiaoying Zhao

4054

Comparison of tumor characteristics and survival between esophageal and other gastroenteropancreatic neuroendocrine neoplasms.

Mehran Taherian

e15556

Comprehensive molecular characterization of clinical response in ramucirumab-treated gastric cancer patients: Phase II trial with integrated genomic profiling.

Seung Kim

4064

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.

Ken Masuda

4049

Correlation of CHAF1A with adjuvant chemotherapy outcome and microsatellite instability in gastric cancer.

Deqiang Wang

e15511

Decreased risk of esophageal squamous cell carcinoma among metformin users in a population-based cohort study.

Qiao-Li Wang

e15507

Derived neutrophil-to-lymphocyte ratio and platelet to lymphocyte ratio as a prognostic marker for patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.

Guoxin Cai

e15575

Disassociation of ARID1A with genomic ancestry and prognostic impact in an admixed cohort of Brazilian patients with gastric cancer (GC).

Helano C. Freitas

e15585

Distribution of urokinase-type plasminogen activator and its receptor in malignant tissues of gastric adenocarcinoma.

Larisa S. Kozlova

e15530

Dosimetric and radiobiological comparison of external beam radiotherapy using simultaneous integrated boost technique for esophageal cancer in different location.

Lu Wang

e15505

Effect of p-PAQR3Thr32 on PD-L1 expression and immune evasion in gastric cancer.

Zhi-Qiang Ling

e15571

Efficacy and safety of conversion therapy using chemotherapy plus anti-angiogenic therapy in unresectable gastric cancer.

Lu chuan Chen

e15510

Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) cancer: Long-term follow up from KEYNOTE-059.

Zev A. Wainberg

4009

Efficacy and safety of sintilimab in combination with XELOX in first-line gastric or gastroesophageal junction carcinoma (GC/GEJC).

Nong Xu

4042

Epigenetic alternate promoter utilization and association with PD-L1 expression in Epstein–Barr virus positive gastric cancer.

Raghav Sundar

e15509

Esophageal cancer: Five years of experience in an oncological reference center.

José Carlos Cessa-Zanatta

e15536

Evaluation of prognostic factors after esophagectomy in which preoperative chemotherapy was successful.

Takashi Ogata

e15568

Expression of CD44 and CD133 in tumor сells of metastatic and non-metastatic gastric cancer.

Aleksandr B. Sagakyants

e15531

Factors predicting poor survival in early gastric cancer: A SEER analysis.

Yanal Mufeed Alnimer

e15548

Final results of early non-invasive gastric cancer detection study using the serum pepsinogen test method in Croatian patients.

Dragan Trivanovic

e15551

First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma.

Yelena Yuriy Janjigian

4011

FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: Interim safety and efficacy results from the phase II RAMIRIS Study (AIO-STO-0415) of the German Gastric Group at AIO.

Sylvie Lorenzen

4023

Genome-wide copy number alteration (CNA) of circulating cell-free DNA (cfDNA) as a prognostic biomarker in esophageal squamous cell carcinoma (ESCC).

Hyeon-Su Im

e15582

Health-related quality of life (HRQoL) of pembrolizumab (pembro) versus physician choice single-agent paclitaxel, docetaxel, or irinotecan in subjects with advanced/metastatic adenocarcinoma (ACC) or squamous cell carcinoma (SCC) of the esophagus that has progressed after first-line standard therapy (KEYNOTE-181).

Antoine Adenis

4048

Homologous recombination deficiency as prognostic marker in metastatic gastric cancer.

Nuno Sousa

4040

Identification of clinically actionable mutations and immunotherapy biomarkers in Chinese esophageal squamous cell carcinoma patients.

Minghui Wang

e15576

Immune biomarker expression in the tumor microenvironment in Chinese patients with esophageal squamous cell carcinoma was explored.

Pengfei Li

e15542

Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastroesophageal cancer.

Lucy Xiaolu Ma

4069

Impact of adjuvant treatment according to gastric cancer molecular subtypes.

Tiago Biachi De Castria

e15513

Impact of age and sex on chemotherapy (CTx) efficacy, toxicity and survival in early oesophagogastric (OG) cancer: A pooled analysis of 3265 patients from four large randomised trials (OE02, OE05, MAGIC & ST03).

Avani Athauda

4022

Impact of Clostridium difficile infection on gastrointestinal malignancies.

Stuthi Perimbeti

e15586

Integrating endogenous peptides analysis and protease mapping for identification of potential serum biomarkers in gastric adenocarcinoma.

Nora Manoukian Forones

e15564

Investigation of enhanced antitumor effects via co-inhibition of Wnt/β-catenin and PI3K/Akt/mTOR signaling pathways in human gastric cancer.

Moon Young Choi

e15553

Investigation to metastasis of regional lymph node station and prediction to long-term survival following esophagectomy in thoracic esophageal cancer with stage T1 to T3.

Yin Li

e15519

Is it possible to effectively treat second-line gastric cancer, given the prognosis factors?

Georgy M. Manikhas

e15570

Is there a correlation between clinic-pathological features, MSI, PD-L1 and survival outcomes in resected gastric cancer? Looking for optimal biomarkers.

Margherita Ratti

e15566

KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.

Yelena Yuriy Janjigian

TPS4146

Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody.

Xi Wang

e15559

Landscape of innate and adaptive immunity targets in oesophagogastric adenocarcinoma (OGA).

Elizabeth Catherine Smyth

4063

Management of synchronous Krukenberg tumors from gastric cancer: A single-center experience.

Pengfei Yu

e15563

Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase 2 trial of the German Gastric Group of the AIO.

Salah-Eddin Al-Batran

TPS4144

Molecular comparison between peritoneal metastases (PM) and primary gastric (GC) and gastroesophageal junction (GEJ) cancer.

Matthew K Stein

4053

Molecular mechanism of chemoresistance and restoration in human gastric cancer cells.

Hye Jung Chang

e15544

Neoadjuvant chemoradiotherapy combined with surgery in the treatment of potentially operable thoracic squamous cell carcinoma of the esophagus(ChiCTR-OIC-17011648): A phase II single center clinical study.

Fang Liu

e15543

Neoadjuvant epirubicyn, oxaliplatin, capecitabine and radiation therapy (NEOX-RT) followed by surgery for locally advanced gastric cancer (LAGC): A phase II multicentric study.

Antonino De Paoli

4066

Neoadjuvant versus adjuvant chemoradiotherapy for stage II–III esophageal squamous cell carcinoma: A propensity score-matched analysis.

Jiahua Lv

e15524

Not all HLA loss facilitate immune escape.

Li Zhang

e15540

Novel genomic prognostic factors for nonsurgical esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy.

Honghai Dai

e15589

Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial.

Peter S Hall

4006

Paratracheal lymph node metastasis in operable localized esophageal and gastroesophageal junction adenocarcinoma.

Kazuto Harada

e15526

Patient-reported distress and symptoms predict post-esophagectomy outcomes.

Jonathan C. Salo

e15567

Patterns of local failure after definitive radiotherapy in patients with esophageal squamous cell carcinoma: Implications for the longitudinal clinical target volume design.

Bo Cheng

e15504

Pembrolizumab in previously treated metastatic esophageal cancer: Longer term follow-up from the phase 2 KEYNOTE-180 Study.

Ken Kato

4032

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.

Manish A. Shah

4010

Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.

Josep Tabernero

LBA4007

Perioperative (P) UGT1A1 genotype guided irinotecan (iri) dosing ‘gFOLFIRINOX’ for gastroesophageal adenocarcinoma (GEA).

Daniel V.T. Catenacci

4050

Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.

Salah-Eddin Al-Batran

TPS4142

Perioperative chemotherapy alone versus preoperative chemoradiotherapy for locally advanced distal esophageal and gastroesophageal junction cancer: A 10-year review of the British Columbia (BC) cancer registry.

Shiru Lucy Liu

4028

PET-directed combined modality therapy for gastroesophageal junction cancer: First results of the prospective MEMORI trial.

Sylvie Lorenzen

4018

Phase 1 open label trial of intraperitoneal paclitaxel (IPP) in combination with intravenous cisplatin (C) and oral capecitabine (X) in patients with advanced gastric cancer and peritoneal metastases.

Sina Vatandoust

4061

Phase 2 study of camrelizumab (anti-PD-1 antibody) combined with apatinib and chemotherapy for the first-line treatment of advanced esophageal squamous cell carcinoma.

Bo Zhang

4033

Phase I study of fluzoparib, a PARP1 Inhibitor in combination with apatinib and paclitaxel in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Jian-Ming Xu

4060

Phase I study of irinotecan/5-fluorouracil/leucovorin (FOLFIRI) with sunitinib for advanced gastroesophageal cancers (EGC).

Sarbajit Mukherjee

e15569

Phase I trial of hyperthermic intraperitoneal chemoperfusion (HIPEC) with cisplatin, mitomycin, and paclitaxel in patients with gastric adenocarcinoma and carcinomatosis or positive cytology.

Brian D. Badgwell

4056

Phase II study of a telomerase-specific oncolytic adenovirus (OBP-301, Telomelysin) in combination with pembrolizumab in gastric and gastroesophageal junction adenocarcinoma.

Uqba Khan

TPS4145

POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) versus FOLFOX as a first-line treatment in advanced gastric cancer (AGC): Update from a multicenter, randomized phase II trial, FNF-004 trial.

Rongbo Lin

4035

Pooled safety analysis from phase 3 studies of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC) and metastatic colorectal cancer (mCRC).

Eric Van Cutsem

4039

Postoperative adjuvant chemotherapy for thoracic pathological T3N0M0 esophageal cancer: A propensity score-matched analysis (APEC Study 1).

Qifeng Wang

e15537

Predictors of peritoneal metastasis in gastric cancer.

Irina V. Kaplieva

e15528

Preoperative CA 19-9 and CEA as predictors of operative outcomes in resectable gastric cancer (GC).

Alexandra Gangi

e15581

Prevalence of esophageal malignant and premalignant lesions in a Michigan cohort, 2013-2017.

Shilpa Tatineni

e15541

Prevalence of gastric cancer and premalignant changes in a Michigan cohort, 2013-2017.

Divyesh Reddy Nemakayala

e15539

Prognostic significance of sarcopenia in metastatic esophageal squamous cell carcinoma.

Kirsty Taylor

4068

Prognostic stratification of locoregional esophageal cancer (EC) patients (pts) treated with definitive chemoradiotherapy (dCRT).

Hyehyun Jeong

e15578

Prognostic value and clinicopathological significance of programmed cell death ligand 1 (PD-L1) expression in resected gastric cancer: A meta-analysis.

Shuixiu Yu

e15512

Prognostic value of serum soluble programmed death-ligand 1 (sPDL1) and dynamics during chemotherapy in advanced gastric cancer patients.

Woochan Park

4034

Prognostic value of systemic immune-inflammation index in elderly patients with esophageal squamous cell cancer.

Shengjun Ji

e15500

Prospective evaluation of metabolic intratumoral heterogeneity using 18F-FDG-PET-CT in patients with advanced gastric cancer receiving palliative chemotherapy.

Shin Hye Yoo

4059

Prospective validation of a serum miRNA panel for early detection of gastric cancer.

Lihan Zhou

4065

Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma.

Haeseong Park

TPS4150

Randomized phase III trial of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer (JCOG0912).

Hitoshi Katai

4020

RAP: A phase II trial with ramucirumab, avelumab, and paclitaxel as second line treatment in gastro-esophageal adenocarcinoma of the arbeitsgemeinschaft internistische onkologie (AIO).

Anica Högner

TPS4148

Recurrence risk evaluation in stage IB gastric cancer with TP53 codon 72 polymorphism.

Satoshi Nishizuka

4044

Relationship between PET response and pathologic response in distal esophageal/gastroesophageal junction cancers: A provincial population-based analysis.

Irene S. Yu

e15506

Role of angiogenesis factors in formation of metastatic niches.

Elena M. Frantsiyants

e15534

S-1 plus oxaliplatin versus S-1 plus cisplatin as first-line treatment for advanced diffuse-type or mixed-type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial.

Rui-hua Xu

4017

Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Results from big ten cancer research consortium study.

Hirva Mamdani

4058

Safety and efficacy of neoadjuvant chemotherapy with S-1 and oxaliplatin plus apatinib for locally advanced gastric cancer.

Ya'nan Zheng

e15503

Safety of neoadjuvant chemoradiation (CRT) in combination with avelumab (A) in the treatment of resectable esophageal and gastroesophageal junction (E/GEJ) cancer.

Nataliya Volodymyrivna Uboha

4041

Safety results of a phase III randomized trial of comparison of three paclitaxel-based regimens concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma (ESO-Shanghai 2).

Dashan Ai

4055

Second-line treatment of metastatic gastric cancer in the era of predictive biomarkers: A cost-effectiveness analysis.

Brianna Lauren

e15517

Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma (GEAC).

Di Maria Jiang

e15579

Survival analysis and clinical characteristics of forty-eight patients with alpha-fetoprotein-positive gastric cancer treated by integrated Chinese and western medicine.

Wenting He

e15550

Survival of gastric cancer (GC) patients is not determined by the predominant genomic ancestry (PGA): Results from an ethnically admixed Brazilian cohort of GC patients.

Helano C. Freitas

e15588

Targeting of survivin to overcome cisplatin resistance in esophageal adenocarcinoma.

Rosalie V. Douglas

e15535

TENERGY: Multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy with 5-FU plus cisplatin in patients with locally advanced esophageal squamous cell carcinoma.

Hideaki Bando

TPS4141

The ctDNA in peritoneal effusion of advanced gastric cancer for auxiliary diagnosis of peritoneal metastasis.

Changsong QI

e15516

The genetic profiles of esophageal squamous cell carcinoma (ESCC) in Hebei, a northern province of China.

Jing Zuo

e15558

The impact of method of recurrence detection on esophageal/gastroesophageal junction (EGJ) cancer outcomes.

Jubin Eghbali Matloubieh

e15580

The impact of postoperative complications on survival outcomes in patients with cT3/4a gastric cancer.

Masanori Tokunaga

4067

The mutational profile analysis of different response to neoadjuvant chemoradiation therapy in local advanced esophageal squamous cell cancer patients.

Xiaofeng Wang

e15560

The prognostic factors associated with long-term survival in the patients with synchronous oligometastatic esophageal adenocarcinoma.

Masaaki Iwatsuki

e15523

The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (QUINTETT).

Richard Malthaner

4052

The ratio of negative lymph node count inside the thoracic cavity to the positive lymph count is a prognostic factor in esophageal squamous cell carcinoma.

Jinling Zhang

e15545

The regulation effect of EGFR signaling pathway on PD-L1 expression on esophageal squamous cell carcinoma cell lines.

Ran Lin Wang

e15577

Tissue plasminogen activator in gastrointestinal adenocarcinoma: What is its role?

Andrey A. Maslov

e15532

Total neoadjuvant chemo (ctx; TNT) for locally advanced gastric cancer (GC): The Memorial Sloan Kettering Cancer Center experience.

Megan Greally

4046

tPA and PAI-1 in malignant tissues of gastric adenocarcinoma can be tumor-associated.

Nikolay S. Samoylenko

e15533

Treatment modalities and oncological outcomes in a cohort of patients with advanced gastric cancer in Mexico.

Ana Karen Valenzuela

e15590

Treatment patterns and outcomes in Chinese gastric cancer by HER2 status: A non-interventional registry study (EVIDENCE).

Shukui Qin

4025

Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.

Kohei Shitara

4037

Trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastroesophageal junction cancer (mGEJC): Subgroup analysis from TAGS.

Wasat Mansoor

4038

Tumor copy number alteration (CNA) burden as a prognostic factor for overall survival in Chinese gastric cancers.

Bo Han

e15555

Tumor mutation burden and immunogenicity in gastric cancer with HER2 alterations.

Bo Wei

4024

Tumor mutational burden identifies chemorefractory gastric cancer with overall survival advantage after receiving toripalimab, a PD-1 antibody.

Rui-Hua Xu

4021

Urokinase secretion by gastrointestinal adenocarcinoma.

Larisa S. Kozlova

e15529